CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 145 enrolled
Drug / intervention
INCAGN01876 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03126110
NCT03126110Phase 2Completed
CompareCT.gov

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Incyte Biosciences International Sàrl·interventional·Posted Apr 24, 2017·Updated Aug 14, 2025

In Brief

A Phase 2 clinical trial evaluating INCAGN01876, Nivolumab, and 1 other intervention for Advanced Malignancies and Metastatic Cancer. Completed, enrolled 145 participants across 38 sites in 4 countries.

Detailed Summary

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Malignancies, Metastatic Cancer
CountriesAustralia, Belgium, Spain, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedApr 24, 2017
Enrollment StartApr 25, 2017
Primary CompletionNov 9, 2021
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 9.2 years ago

Interventions

INCAGN01876drug

In Phase 1 participants will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will be administered IV study drug at the recommended dose from Phase 1 ().

Nivolumabdrug

Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Ipilimumabdrug

Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.